Understand the source comparison
Peptides Help with Detox: [Full Keyword] Comparison
The table below compares three research-grade peptides with documented roles in cellular detoxification pathways. Glutathione, BPC-157, and thymosin alpha-1. Against their mechanisms, evidence base, and practical limitations. Reduced L-Glutathione Directly inc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares three research-grade peptides with documented roles in cellular detoxification pathways. Glutathione, BPC-157, and thymosin alpha-1. Against their mechanisms, evidence base, and practical limitations.
- Reduced L-Glutathione
- Directly increases intracellular GSH; conjugates toxins via GST enzymes; regenerates other antioxidants
- Human trials in NAFLD show 18–22% ALT reduction at 300–600 mg/day for 12 weeks; IV administration raises plasma GSH 40–60% within 90 minutes
- 300–1000 mg daily (oral liposomal or IV)
- IV, liposomal oral, sublingual
- Oral bioavailability is poor without liposomal encapsulation; benefits plateau when hepatic GSH stores are replete
- BPC-157
- Upregulates antioxidant enzymes (SOD, catalase); stabilizes mitochondrial membranes under oxidative stress; enhances angiogenesis in damaged tissue
- Animal models show reduced liver enzyme elevation and histological damage in carbon tetrachloride toxicity; no Phase III human trials
- 200–500 mcg daily (research context)
- Subcutaneous injection, oral
- Human clinical data is sparse; most evidence is preclinical; mechanism in humans requires validation
- Thymosin Alpha-1
- Modulates immune response; enhances autophagy and clearance of damaged proteins; supports hepatic regeneration in chronic liver disease
- Clinical trials in chronic hepatitis B and C show improved viral clearance and reduced fibrosis progression at 1.6 mg twice weekly for 6–12 months
- 1.6 mg twice weekly
- Subcutaneous injection
- Expensive; requires consistent dosing schedule; benefits specific to immune-mediated liver injury